Cytosolic dsRNA improves neonatal innate immune responses to adjuvants in use in pediatric vaccines. Issue 3 (31st January 2022)

• Record Type: Journal Article
• Authors: Brennan, Kiva; Craven, Simon; Cheung, Maria; Kane, Daniel; Noone, Eleanor; O'Callaghan, Joseph; Molloy, Eleanor J; Walsh, Patrick T; McAuliffe, Fionnuala M; Doyle, Sarah L
• Is Part Of: Journal of leukocyte biology. Volume 112:Issue 3(2022)
• Page Start: 523
• Page End: 537
• Publication Date: 2022-01-31
• Subjects: ALUM -- MPLA -- myeloid cell -- Poly(I:C) -- RIG-I -- TLR3; Leucocytes -- Periodicals; Reticulo-endothelial system -- Periodicals; 571.96
• DOI: 10.1002/JLB.5A0521-242R
• Languages: English
• ISSNs: 0741-5400

Abstract

Abstract: Pattern recognition receptors (PRRs) of the innate immune system represent the critical front-line defense against pathogens, and new vaccine formulations target these PRR pathways to boost vaccine responses, through activation of cellular/Th1 immunity. The majority of pediatric vaccines contain aluminum (ALUM) or monophosphoryl lipid A (MPLA) as adjuvants to encourage immune activation. Evidence suggests that elements of the innate immune system, currently being targeted for vaccine adjuvanticity do not fully develop until puberty and it is likely that effective adjuvants for the neonatal and pediatric populations are being overlooked due to modeling of responses in adult systems. We recently reported that the activity of the cytosolic nucleic acid (CNA) sensing family of PRRs is strong in cord blood and peripheral blood of young children. This study investigates the function of CNA sensors in subsets of neonatal innate immune cells and shows that myeloid cells from cord blood can be activated to express T cell costimulatory markers, and also to produce Th1 promoting cytokines. CD80 and CD86 were consistently up-regulated in response to cytosolic Poly(I:C) stimulation in all cell types examined and CNA activation also induced robust Type I IFN and low levels of TNFα in monocytes, monocyte-derived macrophages, and monocyte-derived dendritic cells. We have compared CNA activation to adjuvants currently in use (MPLA or ALUM), either alone or in combination and found that cytosolic Poly(I:C) in combination with MPLA or ALUM can improve expression of activation marker levels above those observed with either adjuvant alone. This may prove particularly promising in the context of improving the efficacy of existing ALUM- or MPLA-containing vaccines, through activation of T cell-mediated immunity. Graphical Abstract: Cytosolic dsRNA activity in neonatal myeloid cells as a pediatric adjuvant.